Recent advances in biosensors for the detection of pancreatic cancer protein markers.
Pancreatic cancer, marked by its low five-year survival rate following surgery and rising incidence, has become one of the most lethal malignant tumors.
APA
Han M, Gao G, et al. (2026). Recent advances in biosensors for the detection of pancreatic cancer protein markers.. Talanta, 296, 128472. https://doi.org/10.1016/j.talanta.2025.128472
MLA
Han M, et al.. "Recent advances in biosensors for the detection of pancreatic cancer protein markers.." Talanta, vol. 296, 2026, pp. 128472.
PMID
40532458
Abstract
Pancreatic cancer, marked by its low five-year survival rate following surgery and rising incidence, has become one of the most lethal malignant tumors. Due to the limitations of conventional diagnostic methods, pancreatic cancer is often diagnosed at advanced stages. Early and minimally invasive detection methods facilitate timely diagnosis and significantly improve survival rates. Developing biosensors with high specificity and sensitivity for detecting protein biomarkers associated with tumor progression represents a promising strategy to achieve this goal. This review provides an overview of various biosensors utilized for detecting pancreatic cancer-related protein biomarkers and biomarker panels. First, it briefly introduces several key protein biomarkers relevant to the clinical detection of pancreatic cancer. Next, it highlights recent advancements in biosensor technology and combined detection methods for improved biomarker identification. Finally, it discusses the challenges and future directions in using biosensors for the early detection of pancreatic cancer.
MeSH Terms
Humans; Biosensing Techniques; Pancreatic Neoplasms; Biomarkers, Tumor; Early Detection of Cancer
같은 제1저자의 인용 많은 논문 (5)
- Therapeutic mechanism of Changyong Decoction in suppressing colorectal cancer progression and inducing ferroptosis via the PIEZO1-PI3K/AKT signaling axis.
- Correction: Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis.
- Disruption of FGL2 induces TFEB-dependent lysosomal degradation of PD-L1 and enhances the efficacy of anti-PD1 therapy in hepatocellular carcinoma.
- Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors.
- Attenuated secreting interleukin-21 activates T-cells and induces anti-tumor effects.